Eisai Co., Ltd. (TYO:4523)

Market Cap	1.46T +9.8%
Revenue (ttm)	808.19B +2.1%
Net Income	42.76B -27.3%
EPS	151.65 -26.6%
Shares Out	281.89M
PE Ratio	34.08
Forward PE	27.52
Dividend	160.00 (3.15%)
Ex-Dividend Date	Mar 30, 2026

Volume	1,627,400
Average Volume	1,730,300
Open	5,125.00
Previous Close	5,077.00
Day's Range	5,085.00 - 5,176.00
52-Week Range	3,463.00 - 5,349.00
Beta	-0.28
RSI	71.29
Earnings Date	Feb 9, 2026

About Eisai

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 10,917
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4523

Financial Performance

In fiscal year 2025, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.